UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
ImmunoGen, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 Par Value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
45253H101
- --------------------------------------------------------------------------------
(CUSIP Number)
- --------------------------------------------------------------------------------
July 29, 2002
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/X/ Rule 13d-1(c)
/ / Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP 45253H101 SCHEDULE 13G -2-
- --------- ----------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Shire BioChem Inc.
- --------- ----------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a) / /
(b) / /
- --------- ----------------------------------------------------------------------
3. SEC Use Only
- --------- ----------------------------------------------------------------------
4. Citizenship or Place of Organization
Canada
- --------- ----------------------------------------------------------------------
5. Sole Voting Power
0
------ ----------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 4,096,098
------ ----------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 0
------ ----------------------------------------------
8. Shared Dispositive Power
4,096,098
- -------------------------- ------ ----------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
4,096,098
- --------- ----------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes
Certain Shares (See Instructions) / /
- --------- ----------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
9.26%
- --------- ----------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
CUSIP 45253H101 SCHEDULE 13G -3-
- --------- ----------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Shire Pharmaceuticals Group Plc
- --------- ----------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a) / /
(b) / /
- --------- ----------------------------------------------------------------------
3. SEC Use Only
- --------- ----------------------------------------------------------------------
4. Citizenship or Place of Organization
England and Wales
- --------- ----------------------------------------------------------------------
5. Sole Voting Power
0
------ ----------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 4,096,098
------ ----------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 0
------ ----------------------------------------------
8. Shared Dispositive Power
4,096,098
- -------------------------- ------ ----------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
4,096,098
- --------- ----------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes
Certain Shares (See Instructions) / /
- --------- ----------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
9.26%
- --------- ----------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
CUSIP 45253H101 SCHEDULE 13G -4-
Item 1(a). Name of Issuer:
ImmunoGen, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
128 Sidney Street, Cambridge, MA 02139
Item 2(a). Name of Person Filing:
This statement is filed on behalf of each of the following persons
(collectively, the "Reporting Persons")
(i) Shire BioChem Inc.
(ii) Shire Pharmaceuticals Group Plc
Item 2(b). Address of Principal Business Office:
(i) Shire BioChem Inc.
275 Armand-Frappier Blvd.
Laval, Quebec
Canada H7V 4A7
(ii) Shire Pharmaceuticals Group Plc
Hampshire International Business Park
Chineham, Basingstoke
RG24 8EP
United Kingdom
Item 2(c). Citizenship:
(i) Shire BioChem is a Canadian corporation.
(ii) Shire Pharmaceuticals Group Plc is a public limited company
organized under the laws of England and Wales.
Item 2(d). Title of Class of Securities:
Common Stock, $.01 par value (the "Shares")
Item 2(e). CUSIP Number:
45253H101
Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c), check whether the person is a:
This Item 3 is not applicable
CUSIP 45253H101 SCHEDULE 13G -5-
Item 4. Ownership:
Shire BioChem Inc.
(a) Amount beneficially owned: 4,096,098
(b) Percent of class: 9.26%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct
the vote: 0
(ii) shared power to vote or to direct
the vote: 4,096,098
(iii) sole power to dispose or to direct
the disposition of: 0
(iv) shared power to dispose or to direct
the disposition of: 4,096,098
Shire Pharmaceuticals Group Plc
(a) Amount beneficially owned: 4,096,098(1)
(b) Percent of class: 9.26%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct
the vote: 0
(ii) shared power to vote or to direct
the vote: 4,096,098
(iii) sole power to dispose or to direct
the disposition of: 0
(iv) shared power to dispose or to direct
the disposition of: 4,096,098
---------
(1): All of the Shares are held by Shire BioChem Inc., a wholly owned
subsidiary of Shire Pharmaceuticals Group Plc.
Item 5. Ownership of Five Percent or Less of a Class:
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company:
Not Applicable
Item 8. Identification and Classification of Members of the Group:
Not Applicable
CUSIP 45253H101 SCHEDULE 13G -6-
Item 9. Notice of Dissolution of Group:
Not Applicable
Item 10. Certification:
By signing below, I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and are held in
the ordinary course of business and were not acquired and are not held
for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are
not held in connection with or as a participant in any transaction
having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: August 7, 2002
SHIRE BIOCHEM INC.
By: Angus Russell
-------------------------------------------
Name: Angus Russell
Title: Director
Dated: August 7, 2002
SHIRE PHARMACEUTICALS GROUP PLC
By: Angus Russell
-------------------------------------------
Name: Angus Russell
Title: Group Finance Director
CUSIP 45253H101 SCHEDULE 13G -7-
EXHIBIT INDEX
Page No.
A. Joint Filing Agreement dated August 7, 2002 by and among Shire BioChem
Inc. and Shire Pharmaceuticals Group
Plc.................................................................... 8
CUSIP 45253H101 SCHEDULE 13G -8-
EXHIBIT A
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13G with
respect to the Common Stock of ImmunoGen, Inc. dated as of August , 2002 is, and
any amendments thereto signed by each of the undersigned shall be, filed on
behalf of each of us pursuant to and in accordance with the provisions of Rule
13d-1(f) under the Securities Exchange Act of 1934.
Dated: August 7, 2002
SHIRE BIOCHEM INC.
By: Angus Russell
-----------------------------------------
Name: Angus Russell
Title: Director
Dated: August 7, 2002
SHIRE PHARMACEUTICALS GROUP PLC
By: Angus Russell
-----------------------------------------
Name: Angus Russell
Title: Group Finance Director